Q2 net income rose 8% yr/yr; diluted EPS increased 13%
Revenue decline driven by lower Nebulized Tyvaso and Remodulin sales amid competition
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$783.30 mln
$805.65 mln (11 Analysts)
Q2 EPS
$7.27
Q2 Net Income
$333 mln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for United Therapeutics Corporation is $695.00, about 34% above its August 4 closing price of $518.68
UTHR•
